Case reports have validated increased MCC diagnoses in patients treated with JAK inhibitors. However, case reports have also described a robust tumor response upon addition of nivolumab despite continuation of ruxolitinib. Thus, it is currently unclear whether ruxolitinib is antagonistic or synergistic to anti-PD1 therapy. This evidence concerns the gene PDCD1 and neoplasm.